Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy

Launched by INSTITUT PAOLI-CALMETTES · Aug 5, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how breast cancer patients respond to a type of treatment called neoadjuvant chemotherapy (NAC), which is given before surgery. The goal is to find out why some patients may not respond well to this treatment. Researchers will analyze tissue samples taken from patients before and after they receive chemotherapy, as well as study small lab-grown versions of the cancer (called Patient-Derived Organoids) and cancer cells found in the blood. By combining these methods, the team hopes to identify specific factors that contribute to drug resistance in breast cancer.

To participate in the trial, women must be over 18 years old and have a confirmed diagnosis of invasive breast cancer. Participants should be planning to undergo chemotherapy followed by surgery, and there are specific health criteria that must be met. During the trial, participants can expect to provide tissue samples and possibly blood samples at several points throughout their treatment. Importantly, if you or someone you know is interested in joining, it's essential to discuss any questions or concerns with a healthcare provider to ensure it’s a good fit.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Woman over 18
• • 2. Signed consent to participate
• • 3. Invasive mammary adenocarcinoma proven histologically and / or cytologically
• • 4. Indication of CNA retention by the referring clinical team.
• • 5. No contraindication to CNA.
• • 6. Selected indication of the post-CNA surgery sequence, then radiotherapy
• • 7. Performance index ≤ 1 (WHO).
• • 8. Affiliation to a social security scheme, or beneficiary of such a scheme
• Exclusion Criteria:
• • 1. Planned therapeutic sequence: CNA, followed by neoadjuvant radiotherapy (HIST-RIC clinical trial for example) before surgery
• • 2. Metastatic disease at diagnosis
• • 3. Patient relapsed from breast cancer precede
• • 4. Other malignant disease in the previous 3 years, with the exception of cervical carcinoma in situ or skin basal cell carcinoma and any other cancerous pathology considered to have been properly treated and at low risk of relapse.
• • 5. Woman pregnant or likely to be (without effective contraception) or breastfeeding
• • 6. Person in an emergency situation, adult person subject to a legal protection measure (adult under guardianship, guardianship or legal protection), or unable to express consent.
• • 7. Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons